The DOI matches its Crossref record.
Approval of Novel TB Drug Celebrated—With Restraint
Abstract
On New Year's Eve, the U.S. Food and Drug Administration approved the first new tuberculosis drug in more than 40 years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“bedaquiline was the first new drug approved in more than 40 years (ref. 121 )”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [121]
Citations
Cited by
Sorted by citations
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A. I., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 921
Nanotechnology approaches for global infectious diseases
Kirtane, A. R., Verma, M., Karandikar, P., Furin, J., Langer, R., & Traverso, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00866-8 · Cited by 520
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
Andries, K., Villellas, C., Coeck, N., Thys, K., Gevers, T., Vranckx, L., Lounis, N., de Jong, B. C., & Koul, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102135 · Cited by 448
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 391
“From these new rug candidates, the semi-synthetic TMC207 has received FDA pproval, specifically for patients with MDR-TB, through its accelerted approval programme which based its decision on Phase II trials Cohen, 2013; Diacon et al., 2009, 2012).”
BackgroundInfluentialProspects for new antibiotics: a molecule-centered perspective
Walsh, C. T., & Wencewicz, T. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.49 · Cited by 385
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 341
“Bedaquiline has been associated with QT-prolongation and must be carefully combined with other drugs that share this risk, including fluoroquinolones, macrolides, clofazimine, or drugs that inhibit CYP3A4, which may increase its exposure [15].”
BackgroundKoul, A., Vranckx, L., Dhar, N., Göhlmann, H. W. H., Özdemir, E., Neefs, J., Schulz, M., Lü, P., Mørtz, E., McKinney, J. D., et al. (2014) · Nature Communications · doi:10.1038/ncomms4369 · Cited by 298
21st Century natural product research and drug development and traditional medicines
Ngô, L., Okogun, J. I., & Folk, W. R. (2013) · Natural Product Reports · doi:10.1039/c3np20120a · Cited by 254
Bactericidal mode of action of bedaquiline
Hards, K., Robson, J. R., Berney, M., Shaw, L. E., Bald, D., Koul, A., Andries, K., & Cook, G. M. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv054 · Cited by 237
Almeida, D. V., Ioerger, T. R., Tyagi, S. K., Li, S., Mdluli, K. E., Andries, K., Grosset, J. H. E., Sacchettini, J. C., & Nuermberger, E. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00753-16 · Cited by 218
“Food and Drug Administration as part of combination therapy for MDR-TB when other alternatives are not available (2).”
BackgroundLi, X., Hernandez, V. S., Rock, F. L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00631 · Cited by 167
Shirude, P. S., Shandil, R. K., Sadler, C., Naik, M., Hosagrahara, V. P., Hameed, S., Shinde, V. N., Bathula, C., Humnabadkar, V., Kumar, N., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401382v · Cited by 167
Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis
Rao, S. P. S., Lakshminarayana, S. B., Kondreddi, R. R., Herve, M., Camacho, L. R., Bifani, P. J., Kalapala, S. K., Jiřiček, J., Ma, N. L., Tan, B. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007355 · Cited by 148
“ScienceT tion for the treatment of MDR TB patients as a part of combination therapy (9).”
BackgroundThe DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis
Riccardi, G., Pasca, M. R., Chiarelli, L. R., Manina, G., Mattevi, A., & Binda, C. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5218-x · Cited by 130
A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis
Fox, G. J., & Menzies, D. (2013) · Infectious Diseases and Therapy · doi:10.1007/s40121-013-0009-3 · Cited by 124
Lü, P., Heineke, M. H., Koul, A., Andries, K., Cook, G. M., Lill, H., van Spanning, R. J. M., & Bald, D. (2015) · Scientific Reports · doi:10.1038/srep10333 · Cited by 123
ATP synthase in mycobacteria: Special features and implications for a function as drug target
Lü, P., Lill, H., & Bald, D. (2014) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2014.01.022 · Cited by 115
Chahine, E. B., Karaoui, L. R., & Mansour, H. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504087 · Cited by 114
“This may shorten the duration of treatment, improve adherence, achieve higher cure rates, and preserve the activity of the background regimen.(41) However, concerns regarding increased mortality restrict bedaquiline use to cases where no alternative options are possible.”
BackgroundTuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm : Figure 1.Preprint
Chakraborty, S., & Rhee, K. Y. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021147 · Cited by 117
“1(5)) is also the first FDA-approved drug to have been developed in the modern era of molecular sciences (Cohen 2013).”
BackgroundAntimicrobial peptides as novel anti-tuberculosis therapeutics
Silva, J. P., Appelberg, R., & Gama, M. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.05.007 · Cited by 107
Current perspectives in drug discovery against tuberculosis from natural products
Nguta, J. M., Appiah‐Opong, R., Nyarko, A. K., Yeboah‐Manu, D., & Addo, P. (2015) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2015.05.004 · Cited by 109
Kondreddi, R. R., Jiřiček, J., Rao, S. P. S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012774 · Cited by 103
Tang, J., Wang, B., Wu, T. S., Wan, J., Tu, Z., Njire, M. M., Wan, B., Franzblauc, S. G., Zhang, T., Lu, X., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00176 · Cited by 96
Alexander, D. C., Vasireddy, R., Vasireddy, S., Philley, J. V., Brown‐Elliott, B. A., Perry, B. J., Griffith, D. E., Benwill, J. L., Cameron, A. D. S., & Wallace, R. J. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02087-16 · Cited by 93
“Food and Drug Administration (FDA) for MDR tuberculosis (TB) treatment in combination with other active tuberculosis drugs (5).”
BackgroundNovel drugs against tuberculosis: a clinician's perspective
Olaru, I. D., von Groote-Bidlingmaier, F., Heyckendorf, J., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00162314 · Cited by 89
Advanced drug delivery and therapeutic strategies for tuberculosis treatment
Nair, A., Greeny, A., Nandan, A., Sah, R. K., Jose, A., Dyawanapelly, S., Junnuthula, V., Athira, K. V., & Sadanandan, P. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02156-y · Cited by 99
Lu, X., Williams, Z. C., Hards, K., Tang, J., Cheung, C., Aung, H. L., Wang, B., Liu, Z., Hu, X., Lenaerts, A. J. M., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00225 · Cited by 84
Metabolic and Bactericidal Effects of Targeted Suppression of NadD and NadE Enzymes in Mycobacteria
Rodionova, I. A., Schuster, B. M., Guinn, K. M., Sorci, L., Scott, D. A., Li, X., Kheterpal, I., Shoen, C. M., Cynamon, M. H., Locher, C. P., et al. (2014) · mBio · doi:10.1128/mbio.00747-13 · Cited by 82
Tomatidine Is a Lead Antibiotic Molecule That Targets Staphylococcus aureus ATP Synthase Subunit C
Boulet, M. L., Isabelle, C., Guay, I., Brouillette, É., Langlois, J.-P., Jacques, P., Rodrigue, S., Brzeziński, R., Beauregard, P. B., Bouarab, K., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02197-17 · Cited by 81
“Bedaquiline, now approved for the treatment of Mycobacterium tuberculosis infections (39), is an ATP synthase subunit C inhibitor specific to Mycobacterium (10).”
BackgroundStructure–activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis
Meissner, A., Boshoff, H. I., Vasan, M., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.048 · Cited by 78
The role of delamanid in the treatment of drug-resistant tuberculosis
Sloan, D. J., & Lewis, J. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s71076 · Cited by 77
“the diarylquinoline ATP-synthase inhibitor, bedaquiline, was the first new anti-TB agent to be licensed since rifampicin in 1967.(15) Two members of the dihydro-nitroimidazole class (delamanid [formerly OPC-67863] and pretomanid [formerly PA-824]) are also undergoing advanced clinical assessment.”
The role of moxifloxacin in tuberculosis therapy
Gillespie, S. H. (2016) · European Respiratory Review · doi:10.1183/16000617.0085-2015 · Cited by 77
Tenero, D. M., Derimanov, G. S., Carlton, A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00240-19 · Cited by 75
Moodley, S., Koorbanally, N. A., Moodley, T., et al. (2014) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2014.06.014 · Cited by 64
Sharma, A. B., Dutta, P., Sharma, M., Rajput, N. K., Dodiya, B., Georrge, J. J., Kholia, T., & Bhardwaj, A. (2014) · Journal of Cheminformatics · doi:10.1186/s13321-014-0046-2 · Cited by 59
Targeting the ATP synthase in bacterial and fungal pathogens: beyond Mycobacterium tuberculosis
Vestergaard, M. R., Bald, D., & Ingmer, H. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.01.026 · Cited by 62
Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents
Lv, K., You, X., Wang, B., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00106 · Cited by 61
Wang, Z., Soni, V., Marriner, G. A., Kaneko, T., Boshoff, H. I., Barry, C. E., & Rhee, K. Y. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907946116 · Cited by 65
“On this basis, BDQ was approved by the US Food and Drug Administration for the treatment of pulmonary multidrug-resistant TB as part of combination therapy in adults (13).”
MethodSAR analysis of new anti-TB drugs currently in pre-clinical and clinical development
Poce, G., Cocozza, M., Consalvi, S., & Biava, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.08.066 · Cited by 60
Recent advances in the development of vaccines for tuberculosis
Ahsan, M. J. (2015) · Therapeutic Advances in Vaccines · doi:10.1177/2051013615593891 · Cited by 57
“However, both dugs induce arrhythmia, and are recommended only in patients for whom other treatment has failed [Cohen, 2013; Ryan and Lo, 2014] (http://www.ema.europa.eu).”
BackgroundXu, J., Converse, P. J., Upton, A. M., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02418-20 · Cited by 57
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents
Ng, P. S., Manjunatha, U. H., Rao, S. P. S., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.10.008 · Cited by 56
Zhou, F.-W., Lei, H. J., Li, F., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.010 · Cited by 53
Almeida, D., Converse, P. J., Li, S.-Y., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01412-21 · Cited by 49
“(FDA) for treatment of tuberculosis (TB) in four decades (1).”
BackgroundMills, H. L., Cohen, T., & Colijn, C. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005260 · Cited by 49
“As new TB drugs are introduced to themarket (40), the opportunity to use these drugs as monotherapy among contacts of individuals with highly drug-resistant disease has been suggested (41).”
Xu, J., Tasneen, R., Peloquin, C. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01692-17 · Cited by 49
New Drugs and Treatment Regimens
Sloan, D. J., Davies, G., & Khoo, S. (2013) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x113099990017 · Cited by 48
“In view of the urgent need for new drugs, the US Food and Drug Administration granted accelerated approval and licensing of bedaquiline for use in MDR-TB regimens in 2012 [63].”
BackgroundGao, C., Peng, C., Shi, Y., You, X., Ran, K., Xiong, L., Ye, T.-H., Zhang, L., Wang, N., Zhu, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep29717 · Cited by 48
New drugs for the treatment of Mycobacterium tuberculosis infection
AlMatar, M., AlMandeal, H., Var, İ., Kayar, B., & Köksal, F. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.105 · Cited by 49
Igarashi, M., Ishizaki, Y., & Takahashi, Y. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.126 · Cited by 46
Hards, K., Cheung, C., Waller, N. J. E., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03110-8 · Cited by 46
de Melo, C. S., Feng, T., van der Westhuyzen, R., Gessner, R. K., Street, L. J., Morgans, G. L., Warner, D. F., Moosa, A., Naran, K., Lawrence, N., et al. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.10.021 · Cited by 47
Current advances in the clinical development of anti-tubercular agents
Tetali, S. R., Kunapaeddi, E., Mailavaram, R. P., Singh, V., Borah, P., Deb, P. K., Venugopala, K. N., Hourani, W., & Tekade, R. K. (2020) · Tuberculosis · doi:10.1016/j.tube.2020.101989 · Cited by 45
Albesa-Jové, D., Chiarelli, L. R., Makarov, V., Pasca, M. R., Urresti, S., Mori, G., Salina, E. G., Vocat, A., Comino, N., Mohorko, E., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500149m · Cited by 45
Lu, X., Tang, J., Cui, S., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.030 · Cited by 44
Wu, Z., Lu, Y., Li, L., Zhao, R., Wang, B., Lv, K., Liu, M., & You, X. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00330 · Cited by 45
Rehberg, N., Akoné, S. H., Ioerger, T. R., Erlenkamp, G., Δαλέτος, Γ., Gohlke, H., Proksch, P., & Kalscheuer, R. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00055 · Cited by 45
TARGETING DORMANT BACILLI TO FIGHT TUBERCULOSIS
Fattorini, L., Piccaro, G., Mustazzolu, A., & Giannoni, F. (2013) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2013.072 · Cited by 47
Zhang, R., Lv, K., Wang, B., et al. (2017) · RSC Advances · doi:10.1039/c6ra25712g · Cited by 43
Zhang, D., Liu, Y., Zhang, C., et al. (2014) · Molecules · doi:10.3390/molecules19044380 · Cited by 42
“Despite the progress, there is still an urgent need for new and more effective therapy for the treatment MDR-TB and repurposing or optimizing existing antibiotics has been proved an effective approach in identifying new TB drugs [2,4].”
BackgroundCholesterol metabolism: a potential therapeutic target in Mycobacteria
Abuhammad, A. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13694 · Cited by 42
“These efforts culminated in the approval of two new drugs for the treatment of MDR-TB as part of a combination regimen: the ATP synthase inhibitor bedaquiline (Andries et al., 2005; Cohen, 2013; Pym et al., 2015) and delamanid (Blair and Scott, 2015; Gupta et al., 2015; WHO, 2015).”
BackgroundDesign, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety
Lv, K., Tao, Z., Liu, Q., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.060 · Cited by 41
Evans, J. C., & Mizrahi, V. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00812 · Cited by 38
“…led to the recent development of bedaquiline (Sirturo; Andries et al., 2005), the first FDA-approved drug for the treatment of TB in over 40 years (Cohen, 2013); delamanid (Deltyba), which received conditional approval by the European Medicines Agency in 2013 and is being evaluated in a phase 3…”
BackgroundThe contrasting cultures of HIV and tuberculosis care
Daftary, A., Calzavara, L., & Padayatchi, N. (2014) · AIDS · doi:10.1097/qad.0000000000000515 · Cited by 39
Laborde, J., Deraeve, C., & Bernardes‐Génisson, V. (2017) · ChemMedChem · doi:10.1002/cmdc.201700424 · Cited by 39
Shah, N. B., & Duncan, T. M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.665059 · Cited by 36
“Mycobacterial ATP synthase is the target of a new class of antibiotics, the diarylquinolines, and the lead drug, bedaquiline, has been approved for treatment of multidrug-resistant tuberculosis (25, 69).”
BackgroundTanner, L., Denti, P., Wiesner, L., & Warner, D. F. (2018) · IUBMB Life · doi:10.1002/iub.1866 · Cited by 34
Update in Tuberculosis and Nontuberculous Mycobacterial Disease 2012
Menzies, D., & Nahid, P. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0687up · Cited by 32
Kim, T., Hanh, B. T. B., Heo, B. E., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115936 · Cited by 30
“It is a diarylquinoline antibiotic that targets the essential FoF1 ATP synthase [25,26].”
BackgroundTantry, S. J., Shinde, V. N., Balakrishnan, G., et al. (2016) · MedChemComm · doi:10.1039/c5md00589b · Cited by 28
Identification and synthesis of novel inhibitors of mycobacterium ATP synthase
Surase, Y. B., Samby, K., Amale, S. R., Sood, R., Purnapatre, K. P., Pareek, P. K., Das, B., Nanda, K., Kumar, S., & Verma, A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.081 · Cited by 28
Rani, A., Johansen, M. D., Roquet, F., Kremer, L., Awolade, P., Ebenezer, O., Singh, P., Sumanjit, & Kumar, V. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127576 · Cited by 26
Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents
Sharma, K., Tanwar, O., Deora, G. S., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.053 · Cited by 24
Targeting mycobacterial membranes and membrane proteins: Progress and limitations
Kumar, G., & Kapoor, S. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117212 · Cited by 28
Liu, J., Ren, Z., Fan, L., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.11.035 · Cited by 24
Susceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Woods, G. L., Lin, S.-Y. G., & Desmond, E. P. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch76 · Cited by 24
Synthesis of new 7-chloro-4-phenoxyquinoline analogues as potential antitubercular agents
Salve, P. S., & Alegaon, S. G. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-1970-2 · Cited by 22
“Further, bedaquiline, a quinoline derivative was launched as an antitubercular agent recently (Chan et al. 2013; Cohen 2013).”
BackgroundA review of recent advances in anti-tubercular drug development
Umumararungu, T., Mukazayire, M.-J., Mpenda, M., et al. (2020) · Indian Journal of Tuberculosis · doi:10.1016/j.ijtb.2020.07.017 · Cited by 20
Shalini, S., Viljoen, A. J., Kremer, L., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.03.021 · Cited by 20
The Redox State Regulates the Conformation of Rv2466c to Activate the Antitubercular Prodrug TP053
Albesa-Jové, D., Comino, N., Tersa, M., Mohorko, E., Urresti, S., Dainese, E., Chiarelli, L. R., Pasca, M. R., Manganelli, R., Makarov, V., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677039 · Cited by 19
Dihydroartemisinin and its Analogs: A New Class of Antitubercular Agents
Kalani, K., Chaturvedi, V., Trivedi, P., et al. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304142802 · Cited by 19
Filling the Pipeline - New Drugs for an Old Disease
Stehr, M., Elamin, A. A., & Singh, M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026613666131113152908 · Cited by 19
Wang, A., Ma, C., Chai, Y., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112409 · Cited by 18
Safety and Efficacy of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)
Field, S. K. (2013) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s11675 · Cited by 18
Response of Mycobacterium smegmatis to the Cytochrome bcc Inhibitor Q203
Chauhan, P., van der Meulen, S. A., Caetano, J. M. S., Goojani, H. G., Botman, D., van Spanning, R. J. M., Lill, H., & Bald, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810331 · Cited by 17
Xu, J., Li, D., Shi, J., Wang, B., Ge, F., Guo, Z., Mu, X., Nuermberger, E. L., & Lu, Y. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01532-22 · Cited by 16
“drug in over 4 decades (2), and it is now classified as a group A drug (to be included in”
BackgroundSingh, A., Viljoen, A. J., Kremer, L., et al. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0098 · Cited by 17
Prevention and treatment of tuberculosis in solid organ transplant recipients
Abad, C. L. R., & Razonable, R. R. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1704255 · Cited by 17
“Bedaquiline has a black-box warning due to its potential to induce arrhythmia [101].”
BackgroundScaini, J. L., Camargo, A., Seus, V., et al. (2018) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2018.11.016 · Cited by 16
Li, L., Li, Z., Liu, M., Shen, W., Wang, B., Guo, H., & Lu, Y. (2015) · Molecules · doi:10.3390/molecules21010049 · Cited by 16
Hybridization Approach to Drug Discovery Inhibiting Mycobacterium tuberculosis-An Overview
Zampieri, D., & Mamolo, M. G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200819151342 · Cited by 15
New Era of TB Drug Discovery and Its Impact on Disease Management
Zheng, X., & Av‐Gay, Y. (2016) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-016-0098-0 · Cited by 17
Rani, A., Viljoen, A. J., Sumanjit, et al. (2017) · ChemistrySelect · doi:10.1002/slct.201702220 · Cited by 15
Zárate-Bladés, C. R., Rodrigues, R. F., Souza, P., Rios, W. M., Soares, L. S., Rosada, R. S., Brandão, I. T., Masson, A. P., Floriano, E. M., Ramos, S. G., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23417 · Cited by 15
Bedaquiline: A New Hope to Treat Multi-Drug Resistant Tuberculosis
Patel, R. V., Riyaz, S., & Park, S. J. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026614666140929114822 · Cited by 14
The Crosstalk Between HIV-TB Co-Infection and Associated Resistance in the Indian Population
Jadhav, S., Nair, A., Mahajan, P., & Nema, V. (2024) · Venereology · doi:10.3390/venereology3040015 · Cited by 14
“Collaborative efforts between healthcare providers, researchers, policymakers, and community stakeholders are indispensable for developing evidence-based interventions and achieving sustainable improvements in public health outcomes.”
McNeil, M. B., Cheung, C., Waller, N. J. E., Adolph, C., Chapman, C. L., Seeto, N. E. J., Jowsey, W. J., Li, Z., Hameed, H. M. A., Zhang, T., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.980844 · Cited by 12
“…et al., 2020; Kamariah et al., 2020; Denny, 2021; Choi et al., 2022; Hards et al., 2022), of which frontiersin.org BDQ is the most clinically advanced and was FDA approved for the treatment of multi-drug resistant M. tuberculosis in 2012 (Diacon et al., 2012; Cohen, 2013; Diacon et al., 2014).”
BackgroundMethodNext-generation antimicrobials: from chemical biology to first-in-class drugs
Ang, M. L. T., Murima, P., & Pethe, K. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0645-0 · Cited by 13
“…and single-channel images, the algorithm precisely segments and identifies the nuclei and cytoplasm of mammalian host cells as well as the intracellular parasites infecting the cells to produce various statistical parameters that can be used to assess both drug responses and compound…”
BackgroundHarris, P. W. R., Cook, G. M., Leung, I. K. H., et al. (2016) · Australian Journal of Chemistry · doi:10.1071/ch16499 · Cited by 13
Metadata
- Authors
- Cohen, J.
- Venue
- Science
- Published
- 2013-01-11
- Volume
- 339
- Issue
- 6116
- Pages
- 130-130
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1972806716
- Cited by
- 166
- References
- 0
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 10 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 7 · 2017: 17 · 2016: 18 · 2015: 18 · 2014: 18 · 2013: 24
- Type
- other
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- tuberculosis, drug approval, FDA approval, tuberculosis treatment, drug development
- MeSH terms
- Antitubercular Agents, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Mycobacterium tuberculosis, Quinolines, United States, United States Food and Drug Administration, Drug Approval, Tuberculosis, Multidrug-Resistant, Drug Resistance, Multiple, Bacterial, Diarylquinolines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
